Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 16/20 | 0.76 |
| ▸ | CLK2 | P49760 | 10/20 | 0.76 |
| ▸ | CLK3 | P49761 | 9/20 | 0.76 |
| ▸ | GSK3B | P49841 | 7/20 | 0.50 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22236116 | 0.92 | DYRK1A (0.64) | DYRK1ACLK2CLK3GSK3BMAPK7 | |
| SCHEMBL22235838 | 0.89 | DYRK1A (0.59) | DYRK1ACLK2CLK3GSK3BMAPK7 | |
| SCHEMBL22236189 | 0.88 | DYRK1A (0.59) | DYRK1ACLK2CLK3GSK3BMAPK7 | |
| SCHEMBL22236259 | 0.86 | DYRK1A (0.57) | DYRK1ACLK2CLK3GSK3BMAPK7 | |
| SCHEMBL22258419 | 0.85 | DYRK1A (0.60) | DYRK1ACLK2CLK3GSK3BMAPK7 | |
| SCHEMBL22236190 | 0.83 | DYRK1A (0.52) | DYRK1ACLK2CLK3GSK3B | |
| SCHEMBL22236034 | 0.79 | DYRK1A (0.54) | DYRK1ACLK2CLK3GSK3B | |
| SCHEMBL22235785 | 0.78 | DYRK1A (0.47) | DYRK1ACLK2CLK3GSK3BMAPK7 | |
| SCHEMBL22236176 | 0.78 | DYRK1A (0.47) | DYRK1ACLK2CLK3GSK3BMAPK7 | |
| SCHEMBL22258432 | 0.77 | DYRK1A (0.55) | DYRK1ACLK2CLK3GSK3BMAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000842-A1 | METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-01-05 | — | — | US | disclosed |
| WO-2020150545-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY | SAMUMED, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150545-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY | SAMUMED, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000842-A1 | METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK | CLK2, CLK3, CLK1 | DYRK1A 7/4885CLK2 1/4885CLK3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.